Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8668325 | Journal of Clinical Lipidology | 2018 | 10 Pages |
Abstract
Less than 10% with and 50% of heFH patients without CHD would reach treatment targets with maximal dose statin, but this substantially increases on addition of ezetimibe, CETPi, or PCSK9i. However, considering recently published adherence data, this might be lower in real life, especially in heFH patients with CHD.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Merel L. MD, Joost MD, PhD, Erik S. MD, PhD, Janneke MD, PhD, Joost H.W. MD, PhD, Jacqueline MD, PhD, FRCP, Frank L.J. MD, PhD, Ben P.M. MD, PhD, Jeanine E. MD, PhD, Roeland MD, PhD, John J.P. MD, PhD, G. Kees MD, PhD, MBA,